Ovarian cancer, often called the silent killer, presents one of the most serious health threats women face globally. Its ...

Vintafolide is a novel folate receptor (FR)-targeted agent that has demonstrated clinical activity and a good toxicity profile in patients with ovarian cancer and adenocarcinoma of the lung.

One reason is the fact that much research related to ovarian cancer has focused on strategies combining chemotherapy with ...

High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced ...

By successfully turning the “cold” tumor into “hot” – transforming the tumor microenvironment from having low immune activity to an active immune environment – ERNA-101 may not only lead to improved ...

The US Food and Drug Administration (FDA) has accepted for priority review the new drug application (NDA) for avutometinib to be used in combination with defactinib for the treatment of adults with ...

Findings from a multi-institutional, international study have significantly advanced the understanding of genetic alterations in the BRCA2 gene, a key player in hereditary cancer risk.